Abstract: A smart dandruff analysis system and method are provided for analyzing a severity of a subject's dandruff, and the smart dandruff analysis system has operation module, first neural network module, second neural network module, and classification module. The operation module receives a scalp area image of the subject and transforms the scalp area image into a first feature map. The first neural network module, a Convolutional Neural Network model, electrically connects with the operation module for receiving and transforming the scalp area image into a second feature map. The second neural network module, a Transformer model, electrically connecting with the first neural network module for receiving and transforming the second feature map into a third feature map. The classification module electrically connects with the second neural network module for receiving the third feature map and outputting a rating, wherein the rating is to determine the severity of the subject's dandruff.

Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Abstract: The present invention relates to charts, stacks and methods for evaluating skin color of a mammalian subject. The chart may include a substrate and an indicia visible from a first side of the substrate that includes a plurality of images of mammalian skin tones having varying degrees of yellowness, wherein each indicia is correlated with an index value. Also, the present invention relates to packaged topical cosmetic products that include a skin chart as well as to methods for evaluating anti-aging and skin lightening products.

Abstract: Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination.

Abstract: This method is designed for calculating a quantification indicator for quantifying a dermal reaction on a skin having several chromophores. The method includes illumination of a zone to be characterized on the skin, the skin reaction being included in the zone to be characterized; and measurement of the spectrum of a back scattered radiation coming from the skin after illumination of said zone to be characterized. The method also includes determination, according to the measured spectrum, of an absorption coefficient value for the zone to be characterized, and calculation, according to the absorption coefficient value, of each chromophore concentration. The method includes calculation of the quantification indicator according to each calculated chromophore concentration. The method includes determination, according to the measured spectrum, of a diffusion coefficient value of the zone to be characterized, and the quantification indicator is further calculated according to the diffusion coefficient value.

Abstract: Method for assessing condition of skin and/or scalp by resulted color from the interaction of protein detecting composition with skin and/or scalp sample. Also disclosed is a method for comparing condition of different skin and/or scalp using the above method. Such conditions include, for example, skin healthiness and dandruff condition of scalp.

Abstract: The present invention provides a human photoaged skin model and an animal model, and a method of making the same, for evaluating cosmetics and similar products in terms of their anti-aging or rejuvenating effect.

Abstract: A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function.

Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

Abstract: Provided are methods of determining whether a cell in a tissue site is viable or nonviable. Also provided are methods of debriding tissue from a tissue site. Further provided are kits comprising a compound that distinguishes between viable and nonviable cells and instructions for using the compound on a tissue site. Additionally, the use of a compound that distinguishes between viable and nonviable cells is provided, where the use is to determine whether a cell in a tissue site is viable or nonviable. Also provided is a use of a compound that distinguishes between viable and nonviable cells, where the use is for the manufacture of the above-described kit.

Abstract: This disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.

Abstract: A method for measuring of histamine in an epidermis comprising applying an adhesive article to an epithelium of a mammal; allowing for adherence of epithelial cells to the adhesive article; removing the adhesive article from the epithelium of the mammal; preparing the adhesive article using standard laboratory methods for extraction; extracting histamine from the epithelial cells adhered to said adhesive article; measuring histamine from the epithelial cells adhered to said adhesive article; determining the amount of histamine in the epithelial cells as compared to a baseline sample. Further, a method of objectively measuring the perception of itch in mammals and wherein there is a reduction in histamine from a baseline level which is directly proportional to a reduction in an itch perception.

Abstract: A method and a kit for quantification of at least one predictor promoting at least one multifactorial disease, intended for use in assessment of the risk for developing or progression of the at least one multifactorial disease for a subject are disclosed. The kit comprises a plurality of reservoir units (320), each reservoir unit (320) being arranged to releasably retain a skin irritation agent adapted to provoke an unspecific inflammatory response of skin The kit comprises an estimation unit adapted to estimate a quantification of the at least one predictor on basis of an assessment of the at least one predictor performed by a user on basis of an assessment of the degree of severity of the inflammatory response to the skin irritation agent at each of a plurality of skin sites according to a predetermined inflammatory response criteria performed by the user and relative impact of the at least one predictor on the progress of the at least one multifactorial disease.

Abstract: The present invention is a substance that allows users to monitor temperature changes and appearance cosmetically on the human body by a change in color of the applied substance. It is intended for direct application to the skin and hair. The range of colors can be adjusted depending on the demand for the specific product or desired effect. The product is meant to be a temporary solution to cosmetically visually show the users temperature or change how the user looks. The cosmetic substance can be applied in many different ways and its unique color changing characteristics can be used on many products.

Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

Abstract: The disclosure provides, in part, a method for quantifying cell numbers in vivo. The disclosure comprises a method of quantifying labeled cells by nuclear magnetic resonance techniques and a computer method for the same.

Abstract: The invention relates to a method and apparatus for characterizing the imperfections of the skin. The apparatus comprises: a) a digital camera allowing the taking of at least one digital image of at least one determined skin zone, the said image being defined by a multiplicity of pixels, that is transmitted to a digital image processing device; b) means of splitting the digital image into three color planes: red, green, blue, termed R, G, B, with the aid of the said image processing device; c) means of extracting a single of these planes; d) means of calculating at least one of the following parameters on the basis of this plane: the mean grey level of the image; the surface area of the imperfections of the skin of the said image, some of which are related to aging, such as wrinkles, lines, spots, dark circles, pigmentary imperfections, slackening or loosening zones; the variance of the grey levels over the set of pixels of the image as parameter representative of the homogeneity of the skin.

Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.

Abstract: The disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.

Abstract: Preparations for external application to human and animal skin, comprising: a) a composition in the form of a fluid nanophase system, comprising the components of a1) at least one water-insoluble substance with a water solubility of less than 4 gram per liter, a2) at least one amphiphilic substance (NP-MCA), which has no surfactant structure, does not build structures alone, the solubility of which is between 4 g and 1000 g per liter in water or oil and which does not enrich preferably at the oil-water interface, a3) at least one anionic, cationic, amphoteric and/or non-ionic surfactant, a4) at least one polar protic solvent, in particular having hydroxy functionality, a5) if necessary one or more adjuvants, wherein the percentage relate to the total weight of the composition each; and b) a therapeutic, cosmetic or diagnostically effective agent in a therapeutic, cosmetic or diagnostically effective amount.

Abstract: A topical composition includes a nanoemulsion of a plurality of hydrophobic particles having a hydrophilic coating therein. The hydrophobic particles are derived from the same or different hydrophobic material and each hydrophobic particle has a melting point below the melting point of the respective hydrophobic material. The nanoemulsion further includes one or more pharmaceutically active agents and/or one or more chemiluminescent disease-detecting systems.

Abstract: The invention relates to new non-therapeutic methods allowing the level of skin neurosensitivity and/or the state of neurosensorial skin reactivity of an individual to be evaluated by applying a peripheral nervous system stimulant to one skin area, the method being implemented under conditions of safety and comfort acceptable for the user, irrespective of his or her skin type.

Abstract: The invention provides compositions and methods to generate pilosebaceous units. In one aspect, the invention comprises a biocompatible scaffold and an effective amount of dermal and epidermal precursor cells.

Abstract: Provided are methods of diagnosing a medical condition associated with hypersensitivity to a female reproductive hormone in a subject, with the proviso that the medical condition is not estrogen dermatitis. The method is effected by administering into a skin of the subject at least one female reproductive hormone such as estriol or estrone, and monitoring a reaction to the female reproductive hormone on the skin, wherein a presence of the reaction above a predetermined threshold is indicative of the presence of the medical condition in the subject. Also provided are methods and computing platforms for treating the medical conditions associated with the hypersensitivity to the female reproductive hormone by desensitization.

Abstract: Topical mixtures with ranges of permeability which promote dermal healing, wound stage arrest, skin cooling, and patient comfort through pH adjustment, therapeutic ingredient carriage, water and oxygen delivery, with superior aesthetics and ease of cleaning features.

Abstract: Fasciolosis is an anthropozoonotic disease caused by the Trematoda Fasciola hepatica. This worm is a common parasite of ruminants namely sheep, goats and cattle. Adult worms are usually found in the bile ducts of the final host liver, causing significant economic losses in the animal husbandry industry. The diagnosis of Fasciola hepatica infection, in definitive hosts, is usually done by microscopic identification of parasite eggs in the stools, observation of adult worms in liver ducts, or by serology. However, no diagnostic tool as been described for utilization directly in the animals in the farm. The disclosed subject matter describes a cDNA clone codifying for a 69 amino acids polypeptide and 8 kDa molecular weight, and identified as Fh8 or “fasciolin” (Genbank number AF213970). Results show that the polypeptide FH8 act as an allergen.

Abstract: Test methods for assessing irritation of portions of skin and/or assessing inhibition and/or reduction of such irritation are provided.

Abstract: A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histiocytosis or a negative NCM skin test. Compositions and method for eliciting an immune response to endogenous or exogenous tumor antigens.

Abstract: Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs), compositions containing SPAs, and methods of using these natural and synthetic SPAs and compositions to prevent or treat inflammatory pathologies.

Abstract: The present invention generally relates to the use of tracers, for example, to track a substance that has been administered to a subject. A tracer may be separate from the substance to be administered, or in some cases, the tracer and the substance are chemically bonded to each other. When administered to a subject (e.g., ingested), the tracer and the substance to be administered may be absorbed and/or metabolized by the subject, and the pharmacokinetic activity of the tracer within the subject may be related to the pharmacokinetic activity of the substance. Thus, by following the pharmacokinetic activity of the tracer, the pharmacokinetic activity of the substance may be determined. The tracer itself may be determined within a subject using any suitable method, depending on the tracer. As an example, the tracer may be determined by administering an indicator able to interact with the tracer.

Abstract: A system for characterizing skin condition comprises a spreadable indicator and a reference. The indicator is suitable for application to human skin and visually changeable when in contact with the oil on human skin. The visual change of the indicator is representative of the amount of the oil in contact with the indicator. The reference relates a plurality of possible visual changes of the indicator to a plurality of skin conditions, whereby a user can compare the reference to the visual change of the indicator to characterize a skin condition of human skin due to the amount of the oil on the human skin in contact with the indicator.

Abstract: A convenient to use test method for comparing the relative affinity of surfactants for the skin employs a solid or semisolid matrix for associating a dye or pigment with the skin. The dye or pigment has an affinity to either the skin or a surfactant adsorbed on the skin during personal cleansing. The matrix may include a reagent soluble polymer film or temporary tattoo.

Abstract: Devices for fast easy monitoring of analyte levels, disease, or other physiological changes are provided. In some cases, the devices may include particles or the like that can be placed and read at the site of detection, typically on or in the skin or mucosa. In one embodiment, the particles may include anisotropic particles. Typically the devices will typically provide a visual colorimetic signal, but other signals are possible, such as smell, taste (e.g., release of food acceptable flavor), or tactile (e.g., shape change). The devices are preferably single use, disposable devices, although some may be able to provide multiple readings over a period of time. These devices may be used with any patient and are particularly useful for pediatric and elderly patients, as well as for the military, and people without health insurance.

Abstract: A system and method for enhancing images of ex-vivo or in-vivo tissue produced by confocal microscopy, optical coherence tomography, two-photon microscopy, or ultrasound, is provided by applying to the tissue a solution or gel having an effective concentration of citric or other alpha-hydroxy acid which enhances tissue structures, such as cellular nuclei, in such images. Such concentration may be 3-20% acid, and preferably 5% acid.

Abstract: Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.

Abstract: The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment psoriasis in a subject.

Abstract: Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination.

Abstract: An indicator for characterizing human skin condition includes a flowable carrier, suitable for application to human skin, and at least one dye soluble with oil found on human skin and visually changeable when in solution with oil on human skin. A visual change in the at least one dye is proportional to the amount of the oil present in solution, whereby when the indicator is applied to an area of human skin, and the at least one dye contacts and reacts with the oil in the area, the indicator will display a visual indication of the skin condition in the area based on the amount of the oil in the area.

Abstract: A wound suture containing a solvatochromatic indicator that undergoes a color change in the presence of bacteria often associated with surgical site infection is provided. Such a color change provides a “real time” indication of the onset of infection, which may alert medical staff to apply an appropriate antimicrobial treatment (e.g., antibiotic) to the patient (e.g., human or animal) before a more serious infection occurs. The patient may also be able to accurately monitor the condition of a wound after discharge from the hospital. Further, the lack of a color change may provide the medical staff or patient with the assurance that the area is generally free of infection and clean.

Abstract: The present invention provides a method and apparatus for non-invasive measurement of skin cholesterol. More particularly, one aspect of the invention provides for a device to apply a detector reagent to a selected area of skin. Another an indicator device to produce a visual change corresponding to the amount of detector reagent that is bound in the skin. The method and apparatus of this invention typically do not require any instrumentation for certain embodiments, allowing the invention to be suitable for self-testing, for example, but not limited to, in the home environment. As such the invention is particularly useful to allow individuals to assess their risk of atherosclerosis and related vascular diseases.

Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein.

Abstract: Test methods for assessing irritation of portions of skin and/or assessing inhibition and/or reduction of such irritation are provided.

Abstract: Test methods for assessing irritation of portions of skin and/or assessing inhibition and/or reduction of such irritation are provided.

Abstract: The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.

Abstract: A diagnostic method for assaying schizophrenia in a subject is provided wherein a preparation comprising platelet derived proteins or fractions thereof having a pI above about 6.5 is injected into a subject and the occurrence of delayed type hypersensitivity (DTH) reaction at the site of the injection is determined. A positive DTH reaction indicates that the tested subject has a high likelihood of being schizophrenic. The protein preparation used in the diagnostic method is also provided as well as a method for its preparation and a kit for use in the diagnosis of schizophrenia using the above method.

Abstract: A system and method for enhancing images of ex-vivo or in-vivo tissue produced by confocal microscopy, optical coherence tomography, two-photon microscopy, or ultrasound, is provided by applying to the tissue a solution or gel having an effective concentration of citric or other alpha-hydroxy acid which enhances tissue structures, such as cellular nuclei, in such images. Such concentration may be 3–20% acid, and preferably 5% acid.

Abstract: Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.